Cryo-Cell International Accounts Payable

The latest accounts payable for CCEL is $2.4M as of August 2026. That compares with $2.6M in the prior-year period — down 7.3% year over year. Investors often review this figure alongside Cryo-Cell International's historical trend and sector peers before judging valuation or financial health.

Over the past year, CCEL's accounts payable moved from $2.6M to $2.4M — a 7.3% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Cryo-Cell International's operating scale or balance-sheet position.

A accounts payable figure of $2.4M for CCEL is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting CCEL's accounts payable ($2.4M), review year-over-year change from $2.6M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Cryo-Cell International's accounts payable against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.